SubHero Banner

Repatha (evolocumab) – FOURIER study results

March 17, 2017 – The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study was published in the New England Journal of Medicine. The addition of Amgen’s Repatha (evolocumab) to optimized statin therapy significantly reduced rates of major adverse cardiovascular (CV) events in patients with clinically evident atherosclerotic cardiovascular disease (CVD).

Download PDF